title: Effect of flunixin meglumine on selected physiologic and performance parameters of athletically conditioned thoroughbred horses subjected to an incremental exercise stress test.
abstract: Twelve clinically sound, healthy, athletically conditioned Thoroughbred horses were subjected to an incremental exercise stress test to determine the effects and period of detection of a single dose of flunixin meglumine (1.1 mg/kg by intravenous injection) in serum and urine by ELISA. Flunixin concentrations, performance, and hematologic and clinical chemical parameters were measured. All horses were rotated through four treatment groups of a Latin-square design providing for each horse to serve as its own control. Flunixin meglumine reduced prostaglandin F(1alpha) and thromboxane concentrations that had been increased by intense exercise. Performance parameters did not improve and prostaglandin concentrations did not significantly correlate with total run time. Exercise did not change the flunixin elimination profile in either serum or urine, and concentrations were found to be below the detection limit of the ELISA test within 36 hours in serum and 120 hours in urine.
authors.affiliation: Department of Large Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville 32610, USA.
authors.forename: Patrick T
authors.initials: PT
authors.lastname: Colahan
authors.forename: James E
authors.initials: JE
authors.lastname: Bailey
authors.forename: Chi-Chung
authors.initials: CC
authors.lastname: Chou
authors.forename: Martha
authors.initials: M
authors.lastname: Johnson
authors.forename: Brett L
authors.initials: BL
authors.lastname: Rice
authors.forename: Galin L
authors.initials: GL
authors.lastname: Jones
authors.forename: Joseph P
authors.initials: JP
authors.lastname: Cheeks
mesh_terms: D000324:Adrenocorticotropic Hormone / Q000097:blood; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D001786:Blood Glucose; D003002:Clonixin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000097:blood / Q000494:pharmacology*; D003404:Creatinine / Q000097:blood / Q000652:urine; D015232:Dinoprostone / Q000097:blood; D005080:Exercise Test / Q000187:drug effects / Q000662:veterinary; D005260:Female; D006736:Horses / Q000502:physiology*; D006854:Hydrocortisone / Q000097:blood; D007275:Injections, Intravenous / Q000662:veterinary; D007328:Insulin / Q000097:blood; D008297:Male; D010101:Oxygen Consumption / Q000187:drug effects; D010805:Physical Conditioning, Animal / Q000502:physiology*; D011453:Prostaglandins / Q000097:blood; D011460:Prostaglandins F / Q000097:blood; D013929:Thromboxane B2 / Q000097:blood; D001615:beta-Endorphin / Q000097:blood
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D001786:Blood Glucose; D007328:Insulin; D011453:Prostaglandins; D011460:Prostaglandins F; D013929:Thromboxane B2; D001615:beta-Endorphin; C014558:flunixin meglumine; D000324:Adrenocorticotropic Hormone; D003404:Creatinine; D015232:Dinoprostone; D003002:Clonixin; D006854:Hydrocortisone; C100006:prostaglandin F1